These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
287 related articles for article (PubMed ID: 20452466)
1. The point on the ongoing B-cell depleting trials currently in progress over the world in primary Sjögren's syndrome. Saraux A Autoimmun Rev; 2010 Jul; 9(9):609-14. PubMed ID: 20452466 [TBL] [Abstract][Full Text] [Related]
3. Persistence of immunoglobulin-producing cells in parotid salivary glands of patients with primary Sjögren's syndrome after B cell depletion therapy. Hamza N; Bootsma H; Yuvaraj S; Spijkervet FK; Haacke EA; Pollard RP; Visser A; Vissink A; Kallenberg CG; Kroese FG; Bos NA Ann Rheum Dis; 2012 Nov; 71(11):1881-7. PubMed ID: 22615459 [TBL] [Abstract][Full Text] [Related]
4. Reduction of fatigue in Sjögren syndrome with rituximab: results of a randomised, double-blind, placebo-controlled pilot study. Dass S; Bowman SJ; Vital EM; Ikeda K; Pease CT; Hamburger J; Richards A; Rauz S; Emery P Ann Rheum Dis; 2008 Nov; 67(11):1541-4. PubMed ID: 18276741 [TBL] [Abstract][Full Text] [Related]
5. Tolerance and efficacy of rituximab and changes in serum B cell biomarkers in patients with systemic complications of primary Sjögren's syndrome. Seror R; Sordet C; Guillevin L; Hachulla E; Masson C; Ittah M; Candon S; Le Guern V; Aouba A; Sibilia J; Gottenberg JE; Mariette X Ann Rheum Dis; 2007 Mar; 66(3):351-7. PubMed ID: 16950808 [TBL] [Abstract][Full Text] [Related]
14. Treatment of primary Sjögren's syndrome with anti-CD20 therapy (rituximab). A feasible approach or just a starting point? Meiners PM; Vissink A; Kallenberg CG; Kroese FG; Bootsma H Expert Opin Biol Ther; 2011 Oct; 11(10):1381-94. PubMed ID: 21819314 [TBL] [Abstract][Full Text] [Related]
15. Anti-CD20 antibody in primary Sjögren's syndrome management. Chen S; Liu Y; Shi G Curr Pharm Biotechnol; 2014; 15(6):535-41. PubMed ID: 25213362 [TBL] [Abstract][Full Text] [Related]
16. Efficacy and safety of rituximab treatment in early primary Sjögren's syndrome: a prospective, multi-center, follow-up study. Carubbi F; Cipriani P; Marrelli A; Benedetto P; Ruscitti P; Berardicurti O; Pantano I; Liakouli V; Alvaro S; Alunno A; Manzo A; Ciccia F; Gerli R; Triolo G; Giacomelli R Arthritis Res Ther; 2013 Oct; 15(5):R172. PubMed ID: 24286296 [TBL] [Abstract][Full Text] [Related]
17. BAFF-modulated repopulation of B lymphocytes in the blood and salivary glands of rituximab-treated patients with Sjögren's syndrome. Pers JO; Devauchelle V; Daridon C; Bendaoud B; Le Berre R; Bordron A; Hutin P; Renaudineau Y; Dueymes M; Loisel S; Berthou C; Saraux A; Youinou P Arthritis Rheum; 2007 May; 56(5):1464-77. PubMed ID: 17469105 [TBL] [Abstract][Full Text] [Related]
18. Immune regulation and B-cell depletion therapy in patients with primary Sjögren's syndrome. Abdulahad WH; Kroese FG; Vissink A; Bootsma H J Autoimmun; 2012 Aug; 39(1-2):103-11. PubMed ID: 22341852 [TBL] [Abstract][Full Text] [Related]
19. A pilot study to test the efficacy of oral administration of interferon-alpha lozenges to patients with Sjögren's syndrome. Khurshudian AV Oral Surg Oral Med Oral Pathol Oral Radiol Endod; 2003 Jan; 95(1):38-44. PubMed ID: 12539025 [TBL] [Abstract][Full Text] [Related]
20. Therapeutic potential for B-cell modulation in Sjögren's syndrome. Mariette X Rheum Dis Clin North Am; 2008 Nov; 34(4):1025-33, x. PubMed ID: 18984420 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]